FundComb

Investment and M&A transaction comps

CPG Investment & M&A Transaction Comps

Global CPG and consumer brand investments, capital raises and M&A transactions, including food, beverage, beauty, personal care, supplements and adjacent branded consumer categories.

Consumer CPG Beauty Supplements Food & Beverage Software Healthcare Biotech
287
Reviewed transactions
173
With price data
4.1x
Median EV or valuation / revenue
16.2x
Median EV or valuation / EBITDA
Year Transactions Priced Median EV or valuation / revenue Median EV or valuation / EBITDA
2026 19 11 3.6x 9.9x
2025 18 17 3.4x 12.7x
2024 19 17 3.6x 16.0x
2023 22 20 4.1x 20.9x
2022 20 11 4.9x 20.4x
2021 26 20 4.7x 15.2x
2020 16 11 4.3x 14.7x
2019 9 8 5.0x 18.7x

Sortable transaction comps

CPG transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

1 / 3

Acquisition EV, USD

USD 12B

Investment EV, USD

-

Median EV / revenue

9.3x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

3 shown of 3 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.

Select for comparison
Lactobio
Control
 2023-12-04 L’Oréal Undisclosed - -
ConsumerBeauty And Personal Care Microbiome Research
+4
Microbiome BeautyPersonal Care R&DPrecision ProbioticsProbiotic Research
2022-12-12 Novozymes 12,300 9.3x 26.2x
CPGBiosolutions
+4
Food IngredientsProbiotic IngredientsProbioticsWellness
BioCare Copenhagen
Control (20%)
 - DSM Undisclosed - -
CPGGut Health Ingredients
+3
Probiotic SupplementsProbioticsSupplements
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.